Aromatase inhibitors in gynecologic cancers

Journal of Steroid Biochemistry and Molecular Biology

Volumn 106, Issue 1-5, 2007, Pages 76-80

  Krasner, Carolyn ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aromatase inhibitors; Gynecologic cancer

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; GEFITINIB; GESTAGEN; HYDROXYPROGESTERONE CAPROATE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE;

CANCER RECURRENCE; CYTOREDUCTIVE SURGERY; ENDOMETRIUM CANCER; ENDOMETRIUM SARCOMA; FEMALE GENITAL SYSTEM; GRANULOSA CELL TUMOR; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER; REVIEW;

ANIMALS; AROMATASE INHIBITORS; FEMALE; GENITAL NEOPLASMS, FEMALE; HORMONES; HUMANS; SARCOMA;

EID: 34548405136     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.05.026     Document Type: Review

References (28)

1. Sasado H., and Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr. Rev. 19 (1998) 593-607
2. Ahlgren J., Ellison N., Gottlieb R., Laluna F., Lokich J.J., Sinclair P.R., Ueno W., Wampler G.L., Yeung K.Y., Alt D., and Fryer J.G. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J. Clin. Oncol. 11 (1993) 1957-1968
3. Markman M., Webster K., Zanotti K., Rohl J., and Belinson J. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol. Oncol. 93 (2004) 390-393
4. Hatch K., Beecham J., Blessing J., and Creasman W. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 (1991) 269-271
5. Perez-Gracia J.L., and Carrasco E.M. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol. Oncol. 84 (2002) 201-209
6. Gelmann E.P. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin. Oncol. 24 (1997) S1-65-S1-70
7. Edmonson J.H. Whither tamoxifen. Gynecol. Oncol. 62 (1996) 1-3
8. Williams C.J. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst. Rev. (2001) CD001034
9. Bowman A., Gabra H., Langdon S.P., Lessells A., Stewart M., Young A., and Smyth J.F. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin. Cancer Res. 8 (2002) 2233-2239
10. Papadimitriou C.A., Markaki S., Siapkaras J., Vlachos G., Efstathiou E., Grimani I., Hamilos G., Zorzou M., and Dimopoulos M.A. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66 (2004) 112-117
11. Del Carmen M.G., Fuller A.F., Matulonis U., Horick N.K., Goodman A., Duska L.R., Penson R., Campos S., Roche M., and Seiden M.V. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol. Oncol. 91 (2003) 596-602
12. Krasner C., Debernardo R., Findley M., et al. Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. ASCO Annual Meeting Proceedings. J. Clin. Oncol. 23 (2005) 5063
13. Lynch T.J., and Bell D.W. Sordella RActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
14. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
15. Schilder R., Sill M., Chen X., Darcy K.M., Decesare S.L., Lewandowski G., Lee R.B., Arciero C.A., Wu H., and Godwin A.K. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin. Cancer Res. 11 (2005) 5539-5548
16. Markman M. Hormonal therapy of endometrial cancer. Eur. J. Cancer 41 (2005) 673-675
17. Lentz S.S., Brady M.F., Major F.J., Reid G.C., and Soper J.T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 14 (1996) 357-361
18. Quinn M.A., Cauchi M., and Fortune D. Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate. Gynecol. Oncol. 21 (1985) 314-319
19. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., Soper J.T., and Given F.T. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. 17 (1999) 1736-1744
20. Thigpen T., Brady M.F., Homesley H.D., Soper J.T., and Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 19 (2001) 364-367
21. Ma B.B., Oza A., Eisenhauer E., Stanimir G., Carey M., Chapman W., Latta E., Sidhu K., Powers J., Walsh W., and Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. Int. J. Gynecol. Cancer 14 (2004) 650-658
22. Rose P.G., Brunetto V.L., Van Le L., Bell J., Walker J.L., and Lee R.B. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 78 (2000) 212-216
23. Wade K., Quinn M.A., Hammond I., Williams K., and Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol. Oncol. 39 (1990) 364-367
24. Reich O., and Regauer S. Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma. Gynecol. Oncol. 98 (2005) 173-174
25. Pink D., Linder T., Mrozek K., et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol. Oncol. 101 (2006) 464-469
26. Leunen M., Breugelmans M., De Sutter P., Bourgain C., and Amy J.J. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol. Oncol. 95 (2004) 769-771
27. Maluf F.C., Sabbatini P., Schwartz L., Xia J., and Aghajanian C. Endometrial stromal sarcoma: objective response to letrozole. Gynecol. Oncol. 82 (2001) 384-388
28. Rao G., and Miller D. Hormonal therapy in epithelial ovarian cancer. Expert Rev. Anticancer Ther. 6 (2006) 43-47